NASDAQ:AEON AEON Biopharma (AEON) Stock Price, News & Analysis → Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad) Free AEON Stock Alerts $1.77 +0.18 (+11.32%) (As of 05/8/2024 ET) Add Compare Share Share Today's Range$1.58▼$1.8050-Day Range$1.59▼$15.9552-Week Range$1.38▼$17.17Volume116,521 shsAverage Volume68,754 shsMarket Capitalization$66.89 millionP/E RatioN/ADividend YieldN/APrice Target$18.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media Get AEON Biopharma alerts: Email Address AEON Biopharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside916.9% Upside$18.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment-0.15Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.18) to ($1.16) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.31 out of 5 starsMedical Sector712th out of 905 stocksPharmaceutical Preparations Industry333rd out of 422 stocks 3.5 Analyst's Opinion Consensus RatingAEON Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAEON Biopharma has only been the subject of 1 research reports in the past 90 days.Read more about AEON Biopharma's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for AEON. Previous Next 0.0 Dividend Strength Dividend YieldAEON Biopharma does not currently pay a dividend.Dividend GrowthAEON Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AEON. Previous Next 1.6 News and Social Media Coverage News SentimentAEON Biopharma has a news sentiment score of -0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.36 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for AEON Biopharma this week, compared to 1 article on an average week.Search Interest4 people have searched for AEON on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added AEON Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AEON Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders20.00% of the stock of AEON Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 22.78% of the stock of AEON Biopharma is held by institutions.Read more about AEON Biopharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AEON Biopharma are expected to grow in the coming year, from ($1.18) to ($1.16) per share. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyHow Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that will forever enshrine Obama’s destructive, Marxist vision for America… A plot that could hand him and his allies near-total control over the government, your way of life, and your future.Click here to watch this now before it’s too late. About AEON Biopharma Stock (NASDAQ:AEON)AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine. AEON Biopharma, Inc. is based in Irvine, California.Read More AEON Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AEON Stock News HeadlinesMay 9, 2024 | globenewswire.comAEON Biopharma Provides Update on Development PipelineMay 8, 2024 | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for AEON Biopharma (NASDAQ:AEON)May 9, 2024 | Porter & Company (Ad)How Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that will forever enshrine Obama’s destructive, Marxist vision for America… A plot that could hand him and his allies near-total control over the government, your way of life, and your future.May 7, 2024 | markets.businessinsider.comMaintaining Buy on AEON Biopharma: Potential of ABP-450 Despite Phase 2 SetbackMay 3, 2024 | msn.comNewly Listed Migraine-Focused AEON Biopharma Stock Plunges On Friday - Read Here WhyMay 3, 2024 | finance.yahoo.comUS Equity Markets Close Higher Friday Following Weak Jobs ReportMay 3, 2024 | markets.businessinsider.comAEON Says Preliminary Results From Phase 2 Interim Analysis Of ABP-450 Fails To Meet Primary GoalMay 3, 2024 | globenewswire.comAEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic MigraineMay 9, 2024 | Porter & Company (Ad)How Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that will forever enshrine Obama’s destructive, Marxist vision for America… A plot that could hand him and his allies near-total control over the government, your way of life, and your future.April 18, 2024 | markets.businessinsider.comAEON Biopharma: Buoyant Prospects Following FDA Alignment on Migraine StudiesMarch 30, 2024 | globenewswire.comCORRECTION -- AEON Biopharma Announces Redemption of Public WarrantsMarch 29, 2024 | globenewswire.comAEON Biopharma Announces Redemption of Public WarrantsMarch 29, 2024 | globenewswire.comAEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 28, 2024 | seekingalpha.comLenz stock rallies 22% amid bullish note by Piper SandlerMarch 21, 2024 | investing.comAEON Biopharma secures $15 million in private placementMarch 19, 2024 | globenewswire.comAEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of MigraineMarch 19, 2024 | globenewswire.comAEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase AgreementsFebruary 26, 2024 | edition.cnn.comAEON Biopharma, Inc. Class AFebruary 6, 2024 | finanznachrichten.deDaewoong Pharmaceutical Co., Ltd.: Daewoong Pharmaceutical Announces 2023 Financial ResultsFebruary 1, 2024 | morningstar.comAeon Kyushu Co Ltd 2653January 31, 2024 | seekingalpha.comAEON.WS AEON Biopharma, Inc. WT EXP 072128January 18, 2024 | finance.yahoo.comAEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin ConferenceJanuary 10, 2024 | investing.comAeon Fantasy Co Ltd (4343)December 20, 2023 | morningstar.comXeris Biopharma Holdings Inc XERSDecember 12, 2023 | finance.yahoo.comAEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic MigraineNovember 15, 2023 | finance.yahoo.comAEON Biopharma Inc Reports Q3 2023 Financial Results Amid Clinical AdvancementsNovember 14, 2023 | msn.comAEON Biopharma, Inc. GAAP EPS of -$0.04See More Headlines Receive AEON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AEON Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/29/2024Today5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AEON Previous SymbolNASDAQ:AEON CUSIPN/A CIK1837607 Webwww.aeonbiopharma.com Phone754-220-9229FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$18.00 High Stock Price Target$18.00 Low Stock Price Target$18.00 Potential Upside/Downside+916.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,630,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-46.82% Debt Debt-to-Equity RatioN/A Current Ratio0.48 Quick Ratio0.48 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($4.12) per share Price / Book-0.43Miscellaneous Outstanding Shares37,790,000Free Float30,231,000Market Cap$66.89 million OptionableNot Optionable Beta0.77 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Marc Forth (Age 52)President, CEO & Director Comp: $1.13MDr. Chad K. Oh M.D. (Age 65)Chief Medical Officer Comp: $587.4kMr. Peter A. Reynolds CPA (Age 66)Chief Financial Officer Mr. Alex Wilson (Age 37)Executive VP, Chief Legal Officer & Corporate Secretary Key CompetitorsCheckpoint TherapeuticsNASDAQ:CKPTCalciMedicaNASDAQ:CALCKezar Life SciencesNASDAQ:KZREagle PharmaceuticalsNASDAQ:EGRXAnnovis BioNYSE:ANVSView All CompetitorsInsidersCrown Holdings Grou StrathspeySold 7,380,394 sharesTotal: $73.80 M ($10.00/share)View All Insider Transactions AEON Stock Analysis - Frequently Asked Questions Should I buy or sell AEON Biopharma stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AEON Biopharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AEON shares. View AEON analyst ratings or view top-rated stocks. What is AEON Biopharma's stock price target for 2024? 1 analysts have issued twelve-month target prices for AEON Biopharma's shares. Their AEON share price targets range from $18.00 to $18.00. On average, they predict the company's stock price to reach $18.00 in the next twelve months. This suggests a possible upside of 916.9% from the stock's current price. View analysts price targets for AEON or view top-rated stocks among Wall Street analysts. How have AEON shares performed in 2024? AEON Biopharma's stock was trading at $7.20 at the beginning of 2024. Since then, AEON shares have decreased by 75.4% and is now trading at $1.77. View the best growth stocks for 2024 here. How were AEON Biopharma's earnings last quarter? AEON Biopharma, Inc. (NASDAQ:AEON) released its quarterly earnings data on Friday, March, 29th. The company reported ($0.71) earnings per share (EPS) for the quarter. When did AEON Biopharma IPO? AEON Biopharma (AEON) raised $75 million in an initial public offering on Thursday, October 14th 2021. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. How do I buy shares of AEON Biopharma? Shares of AEON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AEON) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThis 1 Biotech Stock has been shocking the marketsHuge AlertsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsUrgent Nvidia WarningAltimetry348 million Americans lives to END as we know it?The Oxford ClubThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AEON Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
